Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bayhill's BHT-3009 misses MS endpoint

Bayhill (Palo Alto, Calif.) said 0.5 and 1.5 mg

Read the full 96 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE